Oncolytics Biotech, Inc. ONCY

NAS: ONCY | ISIN: CA6823108759   31/05/2024
1,070 USD (-0,93%)
(-0,93%)   31/05/2024
Grafiek Oncolytics Biotech, Inc. Grafiek Oncolytics Biotech, Inc.

Oncolytics Biotech, Inc. in het nieuws

24 mei 2024 · Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action · Persbericht

16 mei 2024 · Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders · Persbericht

15 mei 2024 · Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial · Persbericht

9 mei 2024 · Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights · Persbericht

9 mei 2024 · Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer · Persbericht

8 mei 2024 · Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference · Persbericht

30 april 2024 · Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights · Persbericht

25 april 2024 · Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting · Persbericht

11 april 2024 · Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA · Persbericht

2 april 2024 · Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference · Persbericht

Profiel Oncolytics Biotech, Inc.

Biotechnologie
Gezondheidstechnologie

Werknemers: 33

Aandelen Oncolytics Biotech, Inc.

Beurswaarde: 81,16 miljoen USD

Effecten: 75,85 miljoen

Mijn selecties